top of page

Disappointing Results from Amyloid Reducing Drug Trial

Updated: Sep 26, 2022

As published in the New York Times 6/17/22



A decade-long clinical trial of a potential Alzheimer’s drug, crenezumab from the Roche Group, found that it failed to prevent or slow cognitive decline. The trial involved a number of adults in Colombia who have a genetic mutation that generally leads to the development of Alzheimer's disease when adults are in their mid-40s to mid-50s. The results are a set-back for drugs that target amyloid, which is believed to be instrumental in the development of dementia of the Alzheimer's type. Some positive outcomes were noted as the adults receiving crenezumab fared better than those adults receiving placebos and did not experience the same types of safety issues (such as brain bleeding or swelling) as those adults on other anti-amyloid therapies.

Comments


bottom of page